| Product Code: ETC7750919 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview |
3.1 Japan Country Macro Economic Indicators |
3.2 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market - Industry Life Cycle |
3.4 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market - Porter's Five Forces |
3.5 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.7 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.8 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about menopausal symptoms and their impact on quality of life |
4.2.2 Growing aging population in Japan leading to a larger target demographic for VMS treatment |
4.2.3 Advancements in medical research and technology resulting in more effective treatment options |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval of VMS treatment drugs in Japan |
4.3.2 Cultural taboos and stigma surrounding menopause leading to lower seeking of treatment |
4.3.3 Competition from alternative therapies such as traditional herbal remedies |
5 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends |
6 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Types |
6.1 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Antidepressants, 2021- 2031F |
6.1.4 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Fluoxetine, 2021- 2031F |
6.1.5 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Paroxetine, 2021- 2031F |
6.1.6 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Sertraline, 2021- 2031F |
6.1.7 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hormone Therapy, 2021- 2031F |
6.1.8 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Anticonvulsant, 2021- 2031F |
6.1.9 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Phenobarbital, 2021- 2031F |
6.1.10 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Phenobarbital, 2021- 2031F |
6.2 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Oral, 2021- 2031F |
6.2.3 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.2.4 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, By End-Users |
6.3.1 Overview and Analysis |
6.3.2 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.3.4 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Homecare, 2021- 2031F |
6.3.5 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.4.4 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.4.5 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
7 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Import-Export Trade Statistics |
7.1 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Export to Major Countries |
7.2 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Imports from Major Countries |
8 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Key Performance Indicators |
8.1 Number of clinical trials and research studies conducted on VMS treatments in Japan |
8.2 Patient adherence rates to prescribed VMS treatment regimens |
8.3 Availability and utilization of specialized menopause clinics or healthcare facilities offering VMS treatments |
9 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market - Opportunity Assessment |
9.1 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.3 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.4 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market - Competitive Landscape |
10.1 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenue Share, By Companies, 2024 |
10.2 Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here